EDINBURGH, Scotland,
Sept. 26, 2018 /PRNewswire/
-- Boston Scientific Corporation (NYSE: BSX) today announced
the launch of the GUIDE™ XT System for visualization of Deep Brain
Stimulation (DBS) in Europe. The
GUIDE XT System is the first DBS visualization system built for
directionality that utilizes patient specific anatomy and
stimulation field modeling. This technology provides physicians
with 3-D image planning capability and when used in conjunction
with the Vercise™ DBS Systems, enables physicians to personalize
and optimize DBS treatment.
DBS treats movement disorder symptoms in patients with
Parkinson's Disease, dystonia or essential tremor. The procedure
stimulates a targeted region of the brain through implanted leads
that are powered by a device called an implantable pulse generator
(IPG).
The GUIDE XT System automatically detects the location of the
leads, implanted by a neurosurgeon, in the imaging of the
brain. Following the implant, a clinician programs a
patient's device and the GUIDE XT System can be used to help
visualize the stimulation field and efficiently determine the most
appropriate settings for each patient.
"Current practice for DBS programming can involve multiple
visits and hours of trial and error to identify the right
stimulation settings," said Prof. Dr. Jens
Volkmann, director and chairman of the Department of
Neurology at the University Hospital of Wurzburg, Germany. "Unlike visualization
systems that use a generic atlas, the GUIDE XT System enables us to
visualize the lead placement in the patient's brain. By simulating
and visualizing different stimulation settings, it is much easier
to decide upon initial programming which is likely to yield
beneficial results in a given patient."
"Direct visualization of pertinent structures within an
individual patient's brain is very important in DBS. This is
the 'gold standard' when planning the surgical trajectory
for lead implantation," explained Professor Ludvic Zrinzo, Head of the UCL Unit of
Functional Neurosurgery, Queen
Square, London. "GUIDE XT integrates surgical planning
with radiological verification of lead placement, promising a
smoother workflow and allowing surgeons to better assist
their clinical colleagues when they program DBS
parameters for each patient."
A study found that overall programming time with the
first-generation GUIDE System was significantly shorter than
traditional programming time (n=10, p<0.0001).1
Shorter programming time is beneficial for both physicians and
patients as it can eliminate the need for additional appointments
and reduce prolonged periods of time adjusting the stimulation
settings which can be stressful and tiring.
"The GUIDE XT System is designed to take the complexity out of
DBS programming, providing physicians with individualized and
supplemental information which could lead to better patient
outcomes." said Maulik Nanavaty,
senior vice president and president, Neuromodulation, Boston
Scientific. "Boston Scientific is dedicated to providing advanced
solutions and meaningful innovations to help clinicians improve the
lives of patients through personalized therapy."
Since receiving CE Mark for the Vercise DBS System in 2012,
Boston Scientific has introduced a steady pace of innovation in the
field of DBS including the launch of the Vercise Gevia™ DBS System*
in 2017, which features the Cartesia™ Directional Lead** to provide
rechargeable, magnetic resonance (MR) conditional
system2 with directionality. The company also launched
the Vercise DBS System in the United
States late last year.
GUIDE XT** was developed in partnership with Brainlab AG, a
software-driven medical technology company that helps improve
patient treatment planning and surgical navigation. The exclusive
collaboration between Brainlab and Boston Scientific provides a
comprehensive portfolio covering all key elements of Deep Brain
Stimulation (DBS) therapy for patients and physicians.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for more than 35 years, we advance science for life by
providing a broad range of high performance solutions that address
unmet patient needs and reduce the cost of healthcare. For
more information,
visit www.bostonscientific.eu and connect
on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements are
based on our beliefs, assumptions and estimates using information
available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements
include, among other things, statements regarding our product
launches and product performance and impact. If our underlying
assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially
from the expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could
affect our ability to implement our business strategy and may cause
actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result, readers
are cautioned not to place undue reliance on any of our
forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; the
closing and integration of acquisitions; intellectual property;
litigation; financial market conditions; and future business
decisions made by us and our competitors. All of these factors are
difficult or impossible to predict accurately and many of them are
beyond our control. For a further list and description of these and
other important risks and uncertainties that may affect our future
operations, see Part I, Item 1A – Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission, which we may update in Part II, Item 1A –
Risk Factors in Quarterly Reports on Form 10-Q we have filed
or will file hereafter. We disclaim any intention or obligation to
publicly update or revise any forward-looking statements to reflect
any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.
CONTACTS
Rosie Ireland
EMEA Media Relations
+44 (0)7585 403359
rosie.ireland@bsci.com
Susie Lisa, CFA
508-683-5565 (office)
Investor Relations
Boston Scientific Corporation
BSXInvestorRelations@bsci.com
1 Pavese et al. Traditional trial-and-error versus
neuroanatomical-3D-image software-assisted deep brain stimulation
programming in patients with Parkinson's disease, 2017 WSSFN
Conference, Berlin.
2 1.5 Tesla MRI conditional when all conditions of use
are met.
*The Vercise™ Gevia™ DBS System is not available for use or sale in
the U.S.
**Vercise Cartesia™ Directional Lead and GUIDE XT -
Caution: Investigational Device. Limited by Federal (or
U.S.) law to investigational use only. Not available for sale
in the U.S.